Every year in the U.S., over 1,000 applications for generic drugs are submitted to the FDA. These aren’t just paperwork - they’re the gateway for millions of people to afford life-saving medications. But who pays for the FDA to review them? The answer isn’t taxpayers alone. It’s the drug companies themselves - through something called generic drug user fees.

These fees come from a program called GDUFA - the Generic Drug User Fee Amendments. It started in 2012 and has been renewed twice since, most recently in 2022 to run through 2027. GDUFA isn’t a tax. It’s a system where generic drug makers pay the FDA to review their applications. In return, the FDA commits to faster, more predictable reviews. Without this funding, the process would crawl. With it, the system runs.

How GDUFA Works: The Pay-for-Performance Model

The FDA doesn’t get a blank check from Congress to handle generic drug reviews. In fact, about 75% of the budget for the Office of Generic Drugs comes directly from industry fees. That’s huge. It means the agency can hire more reviewers, upgrade its computer systems, and do more inspections - all because manufacturers pay to have their drugs reviewed.

This isn’t a free-for-all. GDUFA sets clear rules. Companies pay fees for four things:

• Application fees - $124,680 per Abbreviated New Drug Application (ANDA) submitted in FY 2023. This is what you pay when you ask the FDA to approve your generic version of a brand-name drug.
• Program fees - $385,400 per year for any company that has even one approved generic drug on the market. It’s an annual cost of doing business.
• Facility fees - $25,850 per year for each manufacturing site that makes active ingredients or finished pills for approved generics. If you own two factories, you pay twice.
• DMF fees - $25,850 when a drug master file (a technical dossier on how an ingredient is made) is first referenced in an application.

Here’s the key: paying these fees doesn’t guarantee approval. It just gets your application into the review line. The FDA still tests for safety, effectiveness, and quality. The fees just ensure there’s enough staff to do the job.

Why This System Exists: Before GDUFA

Before 2012, the generic drug review process was a mess. Applications piled up. Some took over three years just to get reviewed. Companies didn’t know where they stood. The FDA didn’t have enough money or staff to keep up.

Imagine waiting 36 months just to hear back if your drug could be sold. By then, the patent on the brand-name drug might have expired - and your chance to enter the market was gone. That’s what happened before GDUFA.

Today, the goal is to review 60% of original ANDAs within 15 months. In 2021, the FDA hit 52%. That’s still behind target, but it’s a massive improvement from 30+ months. Communication has gotten better too. Before GDUFA, deficiency letters were vague. Now, 90% of them give clear, actionable feedback. That’s huge for companies trying to fix issues quickly.

Costs Compared: Generic vs. Brand-Name Drugs

There’s a big difference between what generic drug makers pay and what brand-name drug makers pay. For brand-name drugs under PDUFA (the Prescription Drug User Fee Act), the application fee in 2023 was over $3.4 million. For generics? $124,680. That’s less than 4%.

Why the gap? Because brand-name drugs require full clinical trials - testing on humans, safety data, long-term studies. Generic drugs don’t. They just need to prove they’re the same as the brand-name version. So the review is shorter, cheaper, and faster. But there are far more generic applications. In 2022, the FDA received 1,128 ANDAs. Only 68 new brand-name applications came in. The system has to handle volume.

And it does. Since GDUFA started, generic drug approvals have jumped 22% per year. Over 97% of the FDA’s review goals were met in 2021. That’s not luck. It’s funding.

Who Pays the Most - and Who Struggles

The big players - Teva, Sandoz, Mylan - have dozens of approved drugs and multiple factories. For them, GDUFA fees are just part of the cost of doing business. But for small manufacturers? It’s different.

One small company might own just one facility and have three approved generics. Their annual GDUFA fees could be over $100,000. That’s 15% of their entire regulatory budget. Some have said they can’t expand production because they can’t afford the next facility fee.

The FDA knows this. That’s why small businesses can qualify for a 75% fee reduction. But only 18 such requests were approved in 2022. Why? Many don’t know they’re eligible. Others find the paperwork too complex. It’s a gap in the system.

And then there’s the facility fee. If your company owns one factory, you pay $25,850. If you’re part of a larger corporation with 10 factories? You pay $258,500. But the cost per factory is the same. That’s fair - unless you’re a mom-and-pop operation trying to compete with a multinational.

What’s Still Broken

GDUFA has fixed a lot. But not everything.

First, there’s the backlog. Even after 12 years, around 1,500 ANDA applications from before 2012 are still pending. The FDA says it will clear them all by September 2024. That’s good. But it shows how deep the problem ran.

Second, over-the-counter (OTC) drugs aren’t covered. Think cough syrup, antacids, pain relievers. These are huge - a $117 billion market. But they’re regulated under a different, outdated system. No user fees. No real timeline. Experts say expanding GDUFA to cover OTCs could generate $150-200 million a year and bring order to chaos.

Third, market concentration. Even with more generics entering the market, 20% of generic drug categories have only one or two suppliers. That means less competition - and higher prices. GDUFA helps get drugs approved faster, but it doesn’t fix monopolies. That’s a job for the FTC.

Real Impact: Money Saved, Lives Improved

Here’s the bottom line: generic drugs make up 90% of all prescriptions filled in the U.S. But they cost only 23% of what brand-name drugs do. That’s over $125 billion in annual savings.

Thanks to GDUFA, more generics hit the market faster after patents expire. The FTC estimates GDUFA helped increase timely generic entries by 15%. Over the past decade, that’s saved Americans $1.7 trillion.

Imagine a diabetic who can’t afford insulin. Or a heart patient skipping doses because the brand-name pill costs $500. Generic drugs change that. And GDUFA makes sure those generics get approved - not in 3 years, but in 15 months.

What’s Next for GDUFA

The next reauthorization (GDUFA IV) is already being discussed. Ideas include:

• Using real-world data (like patient outcomes from pharmacies) to speed up post-market reviews.
• Expanding coverage to OTC drugs.
• Improving how fees are calculated for corporate affiliates.

The FDA’s 2023-2027 plan aims to cut the ANDA backlog by half by 2025. That’s ambitious. But with $1.20 in user fees for every $1.00 the FDA spends on generic reviews, the program is one of the most cost-effective tools in public health.

It’s not perfect. But it works. And for millions of people who rely on affordable medicines, that’s what matters most.